AAK1: AP2-Associated Protein Kinase 1, a Potential Drug Target and Biomarker

Target Name: AAK1

NCBI ID: G22848

AAK1

AAK1: AP2-Associated Protein Kinase 1, a Potential Drug Target and Biomarker

Introduction

Apoptosis, or cell death, is a natural phenomenon that occurs in the life cycle of all living organisms. It is a critical process that helps maintain tissue homeostasis, removes damaged or dysfunctional cells, and contributes to overall organism health. Protein kinases, such as AAK1 (AP2-associated protein kinase 1), plays a crucial role in regulating apoptosis. In this article, we will explore the role of AAK1 as a potential drug target and biomarker.

AAK1: Structure, Function, and Localization

The protein kinase domain is a structural subunit that consists of a catalytic core and a carboxylic acid residue. AAK1, with its unique N-terminal and C-terminal extensions, has a distinct three-dimensional structure that allows it to interact with various partners, including other proteins, nucleic acids, and drugs.

The N-terminal region of AAK1 is known as the N-terminal domain and is responsible for the formation of a unique N-terminal-C-terminal interaction. This interaction is crucial for AAK1's catalytic activity and plays a significant role in its regulation by various factors, including changes in cellular stress, growth factors, and pH.

The C-terminal region of AAK1 is known as the C-terminal domain and is characterized by a unique structural feature called a \"Promtype.\" The Promtype is a region of the C-terminal domain that can form a protein-protein interaction and is involved in AAK1's regulation by various factors.

In addition to its unique N- and C-terminal extensions, AAK1 also has a distinct His63 residue, which is a common site for protein-protein interactions. This residue is important for AAK1's stability and functions as a critical conformational element.

AAK1 Localization

AAK1 is a protein that can be found in various cellular compartments, including the cytoplasm, the endoplasmic reticulum, and the nuclear envelope. It is a nuclear protein, which means it is primarily localized to the nucleus of the cell.

AAK1 functions as a kinase, which means it can catalyze the transfer of a phosphate group from a regulatory protein to an target protein. This process is known as phosphorylation and is a critical mechanism for the regulation of various cellular processes, including cell growth, apoptosis , and metabolism.

Drugs that interact with AAK1

Several drugs have been shown to interact with AAK1 and inhibit its catalytic activity. These drugs act by binding to AAK1 and preventing it from forming the active catalytic complex with its regulatory partners.

One of the most well-known drugs that interacts with AAK1 is tasigna (IMGN). Tasigna is a monoclonal antibody that targets AAK1 and is currently in clinical trials for the treatment of various cancers.

Another drug that interacts with AAK1 is Poxacomb (BAY 94-94232). Poxacomb is a selective small molecule G-protein coupled receptor (GPCR) antagonist that inhibits AAK1 phosphorylation through its affinity for the GPCR subtype 伪2 receptor.

Biomarkers for AAK1

The deficiency of AAK1 has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, the study of AAK1 is essential for the development of new diagnostic tools and therapeutic targets.

One of the most promising biomarkers for AAK1 is the phosphorylation status of AAK1. The phosphorylation status of AAK1 can be determined by using various techniques, such as Western blotting, immunofluorescence, or biochemical assays.

In addition to phosphorylation, various post-translational modifications, including tyrosination and ubiquitination, have also been reported to be involved in the regulation of AAK1. These modifications can be used as potential biomarkers for AAK1-related diseases.

Conclusion

In conclusion, AAK1 is a protein that plays a critical role in regulating apoptosis and has been implicated in various diseases. Its unique N- and C-terminal extensions, as well as its distinct His63 residue, make it a unique protein with a high potential for drug targeting. The study of AAK1's regulation by various factors, including drugs and biomarkers, is essential for the development of new diagnostic tools and therapeutic targets.

FA

Protein Name: AP2 Associated Kinase 1

Functions: Regulates clathrin-mediated endocytosis by phosphorylating the AP2M1/mu2 subunit of the adaptor protein complex 2 (AP-2) which ensures high affinity binding of AP-2 to cargo membrane proteins during the initial stages of endocytosis (PubMed:17494869, PubMed:11877457, PubMed:11877461, PubMed:12952931, PubMed:14617351, PubMed:25653444). Isoform 1 and isoform 2 display similar levels of kinase activity towards AP2M1 (PubMed:17494869). Preferentially, may phosphorylate substrates on threonine residues (PubMed:11877457, PubMed:18657069). Regulates phosphorylation of other AP-2 subunits as well as AP-2 localization and AP-2-mediated internalization of ligand complexes (PubMed:12952931). Phosphorylates NUMB and regulates its cellular localization, promoting NUMB localization to endosomes (PubMed:18657069). Binds to and stabilizes the activated form of NOTCH1, increases its localization in endosomes and regulates its transcriptional activity (PubMed:21464124)

The "AAK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AAK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets